Project/Area Number |
22591657
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Orthopaedic surgery
|
Research Institution | Kobe University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
AKISUE Toshihiro 神戸大学, 医学研究科, 講師 (90379363)
ICHIKAWA Hideki 神戸学院大学, 薬学部, 教授 (00248105)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 明細胞肉腫 / ホウ素中性子捕捉療法 / BNCT / 骨・軟部腫瘍学 / 担がん動物モデル / 軟部悪性腫瘍 / 悪性黒色腫 / ホウ素 / 担癌動物モデル / 放射線増感剤 |
Research Abstract |
Clear cell sarcoma (CCS) of tendons and aponeuroses is a rare malignant tumor of poor prognosis,with a predilection for youngadults.Although the standard treatment is still wide surgical resection, neither chemotherapy norradiotherapy is effective. Therefore, clearly new therapeutic strategies are required. Recently, boron neutron capture therapy (BNCT) with the use of p-boronophenylalanine (BPA) for malignant melanoma has provided good results. BecauseBPA is requisite for the production of melanin, boron is finally accumulated in tumor cells. CCS also produces melanin, and with the use of a cultured human CCS cell line andthrough human CCS-bearing animal studies, we have shown that the high accumulation of 10B is potentially favorable in BNCT. Therefore, we evaluated the short-term efficacy of BNCT for CCS with the use of human CCS cell line-bearing nude mice and have here, for thefirst time, demonstrated that BNCT is a potentially new option for the treatment of human CCS.
|